GPER1 and cancer: These findings are consistent with other studies performed using clinically relevant immunohistochemical staining that have shown that GPER is expressed in the majority of TNBC cases and collectively have implications on rational drug design to combat a type of cancer traditionally thought to be nonresponsive to endocrine therapy [50,51,52]—a subject we will return to later.